Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

In Vitro Metabolism of a New Neuroprotective Agent, KR-31543 in the Human Liver Microsomes : Identification of Human Cytochrome P450

  • Ji, Hye-Young (Drug Metabolism and Bioanalysis Laboratory, College of Pharmacy, Wonkwang University) ;
  • Lee, Seung-Seok (Drug Metabolism and Bioanalysis Laboratory, College of Pharmacy, Wonkwang University) ;
  • Yoo, Sung-Eun (Korea Research Institute of Chemical Technology) ;
  • Kim, Hosoon (AgroPharma Research Institute, Dongbu Hannong Chemical Company) ;
  • Lee, Dong-Ha (AgroPharma Research Institute, Dongbu Hannong Chemical Company) ;
  • Lim, Hong (AgroPharma Research Institute, Dongbu Hannong Chemical Company) ;
  • Lee, Hye-Suk (Drug Metabolism and Bioanalysis Laboratory, College of Pharmacy, Wonkwang University)
  • Published : 2004.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

KR-31543, (2S,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(2 -methyl-2H-tetrazol-5-ylmethyl) amino]-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-2H-1-benzopyran, is a new neuroprotective agent for preventing ischemia-reperfusion damage. This study was performed to identify the metabolic pathway of KR-31543 in human liver microsomes and to characterize cytochrome P450 (CYP) enzymes that are involved in the metabolism of KR-31543. Human liver microsomal incubation of KR-31543 in the presence of NADPH resulted in the formation of two metabolites, M1 and M2. M1 was identified as N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amine on the basis of LC/MS/MS analysis with a synthesized authentic standard, and M2 was suggested to be hydroxy-KR-31543. Correlation analysis between the known CYP enzyme activities and the rates of the formation of M 1 and M2 in the 12 human liver microsomes have showed significant correlations with testosterone 6$\beta$-hydroxylase activity (a marker of CYP3A4). Ketoconazole, a selective inhibitor of CYP3A4, and anti-CYP3A4 monoclonal antibodies potently inhibited both N-hydrolysis and hydroxylation of KR-31543 in human liver microsomes. These results provide evidence that CYP3A4 is the major isozyme responsible for the metabolism of KR-31543 to M1 and M2.

Keywords

References

  1. Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E., and Chenery, R. J., Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270 (1995) https://doi.org/10.3109/00498259509061850
  2. Bork, R. W., Muto, T., Beaune, P. H., Srivastava, P. K., Lloyd, R. S., and Guengerich, F. P., Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem., 264, 910-919 (1989)
  3. Hong, K. W., Kim, K. Y., Lee, J. H., Shin, H. K., Kwak, Y. G., Kim, S. O., Lim, H., and Yoo, S. E., Neuroprotective effect of (2S,3S,4R)-N'-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N-benzyl-guanidine (KR-31378), a benzopyran analog, against focal ischemic brain damage in rats. J. Pharmacol. Exp. Ther., 301, 210-216 (2002) https://doi.org/10.1124/jpet.301.1.210
  4. Kim, J., Ji, H. Y., Lee, S. S., Yoo, S. E., Kim. S. O., Lee, D. H., Lim, H., and Lee, H. S., Metabolism of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543 in the rats using liquid chromatography/electrospray mass spectrometry. Arch. Pharm. Res., 25, 664-668 (2002) https://doi.org/10.1007/BF02976941
  5. Lee, M. H., Bae, S. K., Kim, E. J., Kim, Y. G., Kim, S. O., Lee, D. H., Lim, H., Yoo, S. E., and Lee, M. G., Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J. Pharm. Sci., 92, 190-201 (2003) https://doi.org/10.1002/jps.10289
  6. Lillibridge, J. H., Liang, B. H., Kerr, B. M., Webber, S., Quart, B., Shetty, B., and Lee, C. A., Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Disp., 26, 609-616 (1998)
  7. Maurice, M., Pichard, L., and Daujat, M., Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J., 6, 752-758 (1992)
  8. Merry, C., Barry, M. G., Ryan, M., Tjia, J. F., Hennesy, M., Eagling, V.A, Mulcahy, F., and Back, D. J., Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS, 13, F101-F107 (1999). https://doi.org/10.1097/00002030-199910220-00001
  9. Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T., and Woods, H. F., Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Therap., 247, 242-247 (1988)
  10. Sesardic, D., Boobis, A. R., and Murray, B. P., Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br. J. Clin. Pharmacol., 29, 651-663 (1990) https://doi.org/10.1111/j.1365-2125.1990.tb03686.x
  11. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423 (1994)
  12. von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W, Duan, S. X., Fogelman, S. M., Daily, J. P, Harmatz, J. S., and Shader, R. I., Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J. Clin. Pharmacol., 38, 106-111 (1998) https://doi.org/10.1002/j.1552-4604.1998.tb04398.x
  13. Wang, J. S., Wen, X., Backman, J. T., Taavitsainen, P., Neubonnen, P. J., and Kivisto, K. T., Midazolam $\alpha$-hydroxy-lation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol. Toxicol., 85, 157-161 (1999) https://doi.org/10.1111/j.1600-0773.1999.tb00085.x
  14. Watkins, P. B., Wrighton, S. A., Mauel, P., Schuets, E. G., Mendezpicon, G., Parker, G. A., and Guzelian, P. S., Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA, 82, 6310-6314 (1985) https://doi.org/10.1073/pnas.82.18.6310
  15. Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., and Vandenbranden, M., Studies on the expression and metabolic capabilities of human liver cytochrome P-450 IIIA4 (HLp 3). Mol. Pharmacol., 38, 207-213 (1990)
  16. Wrighton, S. A. and Ring B. J., Inhibition of human CYP3A catalyzed 1-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm. Res., 11, 921-924 (1994) https://doi.org/10.1023/A:1018906614320
  17. Yoo, S. E., Vi, K. Y., Lee, S., Suh, J., Kim, N., Lee, B. H., Seo, H. W., Kim, S. O., Lee, D. H., Lim, H. and Shin, H. S., A novel anti-ischemic ATP-sensitive potassium channel opener without vasorelaxation: N-(6-aminobenzopyranyl)-N'-benzyl-N'cyanoguanidine analogue. J. Med. Chem., 44, 4207-4215 (2001) https://doi.org/10.1021/jm010183f